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PDE4 (phosphodiesterase-4)-selective inhibitors have attracted
much attention as potential therapeutics for the treatment of both
depression and major inflammatory diseases, but their practical
application has been compromised by side effects. A possible
cause for the side effects is that current PDE4-selective inhibitors
similarly inhibit isoforms from all four PDE4 subfamilies. The
development of PDE4 subfamily-selective inhibitors has been
hampered by a lack of structural information. In the present study,
we rectify this by providing the crystal structures of the catalytic
domains of PDE4A, PDE4B and PDE4D in complex with the
PDE4 inhibitor NVP {4-[8-(3-nitrophenyl)-[1,7]naphthyridin-6-
yl]benzoic acid} as well as the unliganded PDE4C structure. NVP
binds in the same conformation to the deep cAMP substrate pocket
and interacts with the same residues in each instance. However,
detailed structural comparison reveals significant conformational
differences. Although the active sites of PDE4B and PDE4D are
mostly comparable, PDE4A shows significant displacements of
the residues next to the invariant glutamine residue that is critical
for substrate and inhibitor binding. PDE4C appears to be more
distal from other PDE4 subfamilies, with certain key residues
being disordered. Our analyses provide the first structural basis
for the development of PDE4 subfamily-selective inhibitors.
Key words: cAMP phosphodiesterase, 4-[8-(3-nitrophenyl)-[1,7]-
naphthyridin-6-yl]benzoic acid (NVP), phosphodiesterase-4
crystal structure, phosphodiesterase-4 inhibitor.
INTRODUCTION
Cyclic nucleotide PDEs (phosphodiesterases) hydrolyse the
second messengers cAMP and cGMP, which act as key regulators
of many important physiological processes [1–4]. PDEs provide
the sole means of inactivating these cyclic nucleotides and thus
play pivotal regulatory roles. The human genome encodes 21 PDE
genes that are categorized into 11 families. Alternative mRNA
splicing of the 21 genes generates approx. 100 isoforms of PDEs
in various human tissues. The conservation of these genes implies
important physiological functions.
PDE family-selective inhibitors have been widely studied as
therapeutics, including cardiotonic agents, vasodilators, smooth
muscle relaxants, antidepressants, anti-thrombotics, anti-asthma-
tics and agents for treatment of COPD (chronic obstructive
pulmonary disease) and for improvement of learning and
memory [5–10]. The PDE5 selective inhibitors sildenafil (Viagra),
vardenafil (Levitra) and tadalafil (Cialis) are the best known
examples and have been successfully deployed as therapeutics for
treatment of male erectile dysfunction. PDE4-selective inhibitors
form the largest group of molecules that have been developed
among any PDE families. These inhibitors have been extensively
studied as anti-inflammatory therapeutics for treatment of asthma
and COPD, and also for rheumatoid arthritis, multiple sclerosis,
Type 2 diabetes, septic shock, leukaemia, atopic dermatitis and
other autoimmune diseases [9–12]. More recently, there has been
rekindling of interest in the potential use of PDE4-selective
inhibitors for treating both depression and affective disorders such
as schizophrenia [13,14].
The obstacles preventing PDE4 inhibitors from practical
application are side effects such as nausea and emesis, which
limit the effective therapeutic window [10–12]. Although the
exact mechanisms underpinning the side effects of current
PDE4-selective inhibitors are unclear, one source is thought
to be their non-selective inhibitory effects on the four PDE4
subfamilies (A, B, C and D) [9]. This concept has gained
considerable support from the studies on both targeted knockout
of specific PDE4 genes in mice, cell-based analysis of siRNA
(small interfering RNA)-mediated knockdown of specific PDE4
subfamilies and dominant-negative strategies [15–20]. These
studies have identified unique non-redundant roles for PDE4 sub-
families and isoforms, indicating that PDE4 subfamily-selective
inhibitors may offer a route for maximizing therapeutic actions
while minimizing side effects. The abundance of PDE4B in
neutrophils and monocytes [21], coupled with targeted gene
knockout studies [15,17], suggests that PDE4B is the likely target
for the anti-inflammatory actions of PDE4-selective inhibitors.
This argument is supported by the observations that anti-
inflammatory activity is correlated with the inhibition of PDE4A
and PDE4B [16,22] and is unaffected in mice with PDE4D gene
knockout [23]. In addition, studies on PDE4D-knockout mice
suggest that PDE4D may be connected with the central-nervous-
system-related emetic [24] and cardiac [25] side effects. On the
other hand, PDE4D has recently been shown to play a predominant
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role in T-cell proliferation [26], implying irreplaceable roles
of individual PDE4 subfamilies in cellular processes and the
therapeutic value of PDE4 subfamily-selective inhibitors.
Some attempts have been made to develop PDE4 inhibitors
that selectively discriminate between the four PDE4 subfamilies
in the anticipation that they will have less severe side effects.
However, only very few PDE4 subfamily-selective inhibitors
have been reported to date [27,28], probably due to the lack of
comparative structural information for the active sites of the four
PDE4 subfamilies. An example of a PDE4 subfamily selective
inhibitor is NVP {4-[8-(3-nitrophenyl)-[1,7]naphthyridin-6-
yl]benzoic acid}, which has been demonstrated to show selectivity
for PDE4D (88-, 49- and 68-fold compared with PDE4A, PDE4B
and PDE4C respectively) [27]. Although various structures of
PDE4B and PDE4D in complex with inhibitors are available [29],
no structures of PDE4A, PDE4C or any PDE4 complexes with
subfamily-selective inhibitors have been reported. The present
paper addresses these important deficiencies and reports the
crystal structures of the catalytic domains of PDE4A, PDE4B
and PDE4D in complex with the selective inhibitor NVP, as well
as the structure of the unliganded PDE4C at high resolution. These
structures show that NVP binds to the deep pocket of the active
site and causes subtle, but significant, changes in the conformation
of the active sites of the PDE4 subfamilies.
MATERIALS AND METHODS
Subcloning, expression and purification of PDE catalytic domains
The EST (expressed sequence tag) cDNA clones of PDE4A10
(GenBank® accession number AF073745), PDE4B2B (Gen-
Bank® accession number XM 001862) and PDE4D2 (GenBank®
accession number AF012074) were purchased from the A.T.C.C.
(Manassas, VA, U.S.A.). The human PDE4C2 was reported pre-
viously [30]. The cDNAs for expression of the catalytic domains
of PDE4A10 (residues 290–622), PDE4B2B (residues 152–
487), PDE4C2 (residues 200–558) and PDE4D2 (residues 86–
413) were subcloned into the expression vector pET15b. The
resultant plasmids pET-PDE4A, pET-PDE4B, pET-PDE4C and
pET-PDE4D were transferred into Escherichia coli strain BL21
(Codonplus) cells for overexpression. The E. coli cells carrying
the plasmids were grown in LB (Luria–Bertani) medium at
37 ◦C to a D600 of 0.7 and then 0.1 mM IPTG (isopropyl
β-D-thiogalactoside) was added to induce overexpression at
15 ◦C for 20–40 h. The recombinant proteins of PDE4A10,
PDE4B2B, PDE4C2 and PDE4D2 were passed through an
Ni-NTA (Ni2+-nitrilotriacetate) column (Qiagen), followed by
thrombin cleavage, and purified further using columns of
Q-Sepharose (Amersham Biosciences) and Sephacryl S300
(Amersham Biosciences). A typical batch of purification yielded
approx. 10 mg of PDE4A10, 20 mg of PDE4B2B, 10 mg of
PDE4C2 and 100 mg of PDE4D2 from 2 litres of cell culture.
The purified PDE4 proteins showed a single band by SDS/PAGE
and are estimated to have a purity of >95%.
Protein crystallization and structural determination
All of the crystals of PDE4 subfamilies in complex with NVP were
grown by vapour diffusion. The PDE4–NVP complexes
were prepared by mixing 50 mg/ml PDE4A10-(290–622), 26 mg/
ml PDE4B2B-(150–487) or 30 mg/ml PDE4D2 with 4 mM NVP.
The protein drops consisted of 2 µl of complex solution and 2 µl
of well buffer: 12 % PEG [poly(ethylene glycol)] 400, 200 mM
magnesium acetate, 0.1 M Tris/HCl (pH 8.5) and 5% glycerol
at 4 ◦C for PDE4A10; 12% PEG3350, 0.1 M Tris/HCl (pH 8.5),
35% ethylene glycol and 200 mM MgCl2 at 25 ◦C for PDE4B2B;
and 18% PEG3350, 0.1 Hepes (pH 7.5), 30 % ethylene glycol,
10% propan-2-ol and 200 mM MgCl2 at 4 ◦C for PDE4D2.
The unliganded PDE4C2 at 15 mg/ml (residues 200–558) was
crystallized by the hanging drop method against the well buffer
of 10% PEG3350, 100 mM MgCl2 and 0.1 M Hepes (pH 7.5) at
25 ◦C.
The diffraction data were collected in beamline X29 of
Brookhaven National Laboratory and processed by the program
HKL (Table 1) [31]. The structures were solved by molecular
replacement [32], using the known PDE4D or PDE4B structure
as the initial model. The phases from the molecular replacement
were improved by the density modification package of the CCP4.
The structures were rebuilt by the program O [33] and refined by
the program CNS (Table 1) [34].
Synthesis of the PDE4 selective inhibitor NVP
NVP (Figure 1, left-hand panel) was synthesized by following
the protocol of Hersperger et al. [27], and confirmed by 1H-NMR
{(300 MHz, [2H6]DMSO) δ 9.09 (m, 2H), 8.69 (m, 2H), 8.64 (dd,
1H), 8.40 (m, 3H), 8.11 (d, 2H), 7.87 (m, 2H)] and mass spectrum
[(m/z) [M+H]+ 372}.
Assay of phosphodiesterase activities
The PDE4 enzymes were incubated with a reaction mixture
containing 20 mM Tris/HCl (pH 7.5), 10 mM MgCl2, 1 mM
dithiothreitol and [3H]cAMP or [3H]cGMP (20000 c.p.m./assay)
at room temperature (25 ◦C) for 15 min. The reactions were
terminated by addition of 0.2 M ZnSO4 and 0.2 M Ba(OH)2. The
reaction products [3H]AMP or [3H]GMP were precipitated by
BaSO4, while unreacted [3H]cAMP or [3H]cGMP remained in
the supernatant. Radioactivity in the supernatant was measured
by liquid-scintillation counting. The enzymatic activity was
measured at eight concentrations of cAMP and cGMP with
two or three repeats. For measurement of inhibition, 11 or 12
concentrations of inhibitors were used, together with the
substrate concentration of one-tenth of the Km and the enzyme
concentration for 50% hydrolysis of substrates. The kinetic
parameters Km and kcat were obtained following the theory of
steady-state kinetics.
RESULTS
Enzymatic properties of the PDE4 catalytic domain
Since PDE4 isoforms differ only in their N-terminal regions,
the isoforms PDE4A10 (residues 290–622), PDE4B2B (residues
152–487), PDE4C2 (residues 200–558) and PDE4D2 (resi-
dues 86–413) reflect their core PDE4 subfamily catalytic domains.
As such, we will refer to these as PDE4A, PDE4B, PDE4C
and PDE4D, but keep the residue numbering for the particular
isoforms.
Assayed with their substrate cAMP, the functional PDE4A,
PDE4B, PDE4C and PDE4D catalytic domains exhibited Km
values of 0.8–5.1 µM and kcat values of 0.7–6.7 s−1 (Table 2).
These Km values for the catalytic domains are comparable with
Km values of 1–6 µM for the full-length proteins of the PDE4
subfamilies in the literature [1,21,30,35]. The catalytic domain
derived from PDE4D2 has kcat/Km of 3.5 s−1 ·µM−1, and is approx.
10-fold more efficient than the catalytic domain of PDE4B. Using
cGMP as a substrate, PDE4C and PDE4D have Km values of 0.24
and 0.43 mM, and kcat values of 0.48 and 1.2 s−1 respectively.
However, the kinetic parameters for PDE4A and PDE4B could not
be measured accurately, because of the limited solubility of cGMP
under the assay conditions (Table 2). The substrate specificity
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Table 1 Diffraction data and structural refinement statistics
(a) Data collection
Parameter PDE4A–NVP PDE4B–NVP PDE4C native PDE4D–NVP
Space group P41212 C2221 P6122 P212121
Unit cell (a, b, c, Å) 105.4, 105.4, 166.1 91.8, 105.4, 87.8 74.7, 74.7, 275.9 58.1, 80.6, 163.3
Resolution (Å) 2.1 1.95 1.90 1.57
Total measurements 1479463 375717 1448275 793901
Unique reflections 55625 28299 36952 103916
Completeness (%) 100.0(100.0)* 89.8 (61.6) 99.9 (99.9) 96.4 (72.0)
Average I/σ 9.5 (5.0)* 13.7 (5.0) 8.7 (4.1) 16.1 (2.4)
Rmerge 0.091 (0.53)* 0.064 (0.32) 0.095 (0.63) 0.054 (0.38)
(b) Structural refinement
Parameter PDE4A–NVP PDE4B–NVP PDE4C native PDE4D–NVP
R-factor 0.201 0.213 0.208 0.225
R-free 0.234 (10 %)† 0.239 (10 %) 0.229 (10 %) 0.248 (10 %)
Resolution (Å) 30–2.1 30–1.95 30–1.9 30–1.57
Reflections 53788 27655 36109 99820
RMSD
Bond (Å) 0.006 0.006 0.005 0.005
Angle (◦) 1.10 1.07 1.06 1.04
Average B-factor (Å2)
Protein 37.4 (5404)‡ 42.9 (2707) 32.6 (2332) 26.3 (5271)
NVP 71.7 (56) 45.1 (28) 26.3 (56)
Water molecules 39.1 (269)‡ 41.5 (68) 36.2 (127) 32.696 (365)
Zn 31.1 (2)‡ 38.2 (1) 25.2 (1) 16.5 (2)
Mg 35.2 (2)‡ 42.1 (2) 24.3 (1) 13.8 (2)
* The numbers in parentheses are for the highest resolution shell.
† The percentage of reflections omitted for calculation of R-free.
‡ The number of atoms in the crystallographic asymmetric unit.
Table 2 Kinetic parameters of PDE4
The apparent K m and k cat values were determined from Eadie–Hofstee plots of v0 against v0/[S]. Each value was measured at least twice. Protein concentrations were converted from the ε280 molar
absorption coefficient calculated by the ProtParam program.
K mcAMP k catcAMP (k cat/K m)cAMP K mcGMP k catcGMP (k cat/K m)cGMP IC50 of NVP
(µM) (s−1) (s−1 ·µM−1) (µM) (s−1) (s−1 ·µM−1) (k cat/K m)cAMP/(k cat/K m)cGMP (µM)
PDE4A 5.1 +− 0.5 6.7 +− 0.2 1.3 +− 0.2 >1000 – – – 3.3 +− 0.2
PDE4B 4.5 +− 0.3 1.56 +− 0.05 0.35 +− 0.03 >1000 – – – 0.65 +− 0.01
PDE4C 0.80 +− 0.14 0.66 +− 0.05 0.85 +− 0.18 240 +− 55 0.48 +− 0.10 2.0 +− 0.04 × 10−3 427 5.7 +− 0.2
PDE4D 1.5 +− 0.1 5.4 +− 1.0 3.5 +− 0.7 427 +− 23 1.19 +− 0.02 2.8 +− 0.1 × 10−3 1250 0.57 +− 0.04
Figure 1 Inhibition of PDE4 subfamilies by NVP
Left: chemical structure of NVP. Right: inhibition of NVP on PDE4A (), PDE4B (), PDE4C () and PDE4D (). Results are means +− S.D. of two or three repeated measurements. A substrate
concentration of 0.04 µM cAMP was used in the determination of the IC50 values.
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constants of (kcat/Km)cAMP/(kcat/Km)cGMP are 427 and 1250 for the
catalytic domains of PDE4C and PDE4D, thus indicating their
cAMP specificity. Although the kcat values for cGMP and cAMP
are similar among the PDE4 subfamilies, the Km values are
dramatically different for these two substrates. This suggests that
the cAMP preference of the PDE4 proteins is determined by the
poor affinity of cGMP.
The IC50 values for NVP are 3.3, 0.65, 5.7 and 0.57 µM for
PDE4A, PDE4B, PDE4C and PDE4D respectively (Figure 1,
right-hand panel, and Table 2). Thus the potency of NVP
inhibition on PDE4D and PDE4B is similar, but approx. 10-
fold better than that of PDE4C. Our data concerning the NVP
inhibition of the catalytic domains of each of the four PDE4
subfamilies are significantly different from the earlier reported
values of 88, 49, 68 and 1 nM for PDE4A, PDE4B, PDE4C and
PDE4D respectively [27]. The explanation for this disagreement
is not clear, but there are two possibilities. First, our data
were measured against the defined catalytic domains of the
PDE4 subfamilies, in contrast with undefined full-length proteins
expressed in Saccharomyces cerevisiae in the earlier study [27].
Thus the high selectivity against the full-length PDE4D might
represent the contribution of the N- or C-terminal regions of
the PDE4 subfamilies, although the catalytic domains of the
PDE families such as 4, 7 and 10 have been reported to have
Km and kinetic parameters comparable with those of the full-
length proteins [35,36]. On the other hand, the use of partially
purified proteins in the earlier study may affect the accuracy of
the measurements. In this regard, it has been shown that certain
proteins can interact with full-length PDE4 isoforms and modify
their function [37]. It has also been reported that the full-length
PDE4D3 protein used in the analyses by Hersperger et al. [27] can
be modified in its UCR (upstream conserved regulatory region) 1
by PKA (protein kinase A) phosphorylation, so that its sensitivity
to certain PDE4-selective inhibitors can be altered [38]. Thus any
‘impurities’ in their assay systems might have an impact on the
protein activity or the measurement accuracy.
Structural architecture
The crystallographic asymmetric units contain two catalytic
domains of PDE4A–NVP and PDE4D–NVP, but one of PDE4B–
NVP and unliganded PDE4C. The entire catalytic domains of
PDE4A10 (residues 298–622), PDE4B2B (residues 152–487)
and PDE4D2 (residues 86–411), and the core domain of PDE4C2
(residues 201–332, 346–464 and 491–536) are unambiguously
traced in the structures (Figure 2). Residues 333–345 of the H-loop
and 465–490 of the M-loop in PDE4C lacked electron density and
are disordered. All four structures of the PDE4 subfamilies have
the same folding and secondary structures. This is not surprising
because the catalytic domains of the PDE4 subfamilies have a
high degree of amino acid conservation, in which 254 out of 325
residues (78%) are identical. The superposition of PDE4D on
PDE4A, PDE4B and PDE4C yielded RMSDs (root mean square
deviations) of 0.67, 0.73 and 0.64 Å (1 Å = 0.1 nm) respectively
for the Cα atoms of the comparable residues in the domains,
indicating the overall similarity of the catalytic domain in the
PDE4 subfamilies.
The catalytic domains of the PDE4 subfamilies contain 16 α-
helices (Figure 2), as reported previously [39]. However, helices
H8 and H9 of the H-loop, six tail residues of H14, and four head
residues of H15 in PDE4C are disordered. The catalytic pocket
can be divided further into two major sub-pockets for binding of
bivalent metals and substrates. The metal-binding pocket contains
two bivalent metal ions: a zinc ion that has been confirmed by
the anomalous scattering, together with an unidentified bivalent
metal, presumed to be magnesium, which has been shown to be
important for catalytic activity [4,38,40]. A magnesium ion was
thus used as the second metal in the refinement of all the four
structures and shows a comparable B-factor under full occupancy
(Table 1). Both metal ions form six co-ordinations in an octahedral
configuration. Zinc co-ordinates with His164, His200, Asp201, Asp318
and two water molecules in the PDE4D–NVP structure, whereas
magnesium interacts with Asp201 and five waters molecules. The
metal co-ordination in PDE4A, PDE4B and PDE4C is the same
as that in PDE4D.
Binding of NVP
The inhibitor NVP binds to the active sites of PDE4A, PDE4B
and PDE4D with a similar conformation (Figure 3). The electron-
density maps reveal unambiguously the binding position and
conformation of NVP, although its nitrate group has relatively
weaker density (Figure 3). The carboxyphenyl and naphthyridine
groups form almost a co-plane with an approx. 10◦ tilt, whereas
the nitrophenyl group is approx. 40◦ off the naphthyridine plane
(Figures 3D and 3E). The B-factors of NVPs are comparable
with the average of the protein atoms in the PDE4B and PDE4D
structures (Table 1), suggesting its full occupancy. However,
the B-factor of NVP in the PDE4A structure is significantly
higher (Table 1), implying its partial occupancy. In order to
assess the interaction of NVP with PDE4 subfamily members,
we describe its binding to PDE4D in detail and then compare,
where appropriate, its interaction with other PDE4 subfamilies.
NVP forms only one hydrogen bond between its N1 and Ne2 of
the invariant glutamine at the active site of all PDE4 subfamilies
(Gln369 in PDE4D, Figure 4). NVP is partially buried within the
pocket and has a solvent-accessible area of approx. 10 % in all
three PDE4–NVP complex structures. The naphthyridine group is
completely buried and not accessible. The carboxyphenyl group
orients to the metal-binding pocket and forms hydrogen bonds
with five water molecules, two of which are metal-bound. The
nitrophenyl group of NVP orients its nitrate group towards the
surface of the PDE4 molecules, but, surprisingly, no water binds
to the nitrate groups in most of the PDE4 subfamilies, except
one in the PDE4B structure. A key feature seen in all examples
of NVP binding to the PDE4 subfamilies is its tilted stacking
against the conserved phenylalanine residue (Phe372 in PDE4D)
located in the active site. In most structures of the PDE–inhibitor
complexes, the conserved phenylalanine residue stacks in parallel
to either a benzene group, such as is found in rolipram with PDE4,
or a hydrophobic ring, such as pyrazolopyrimidinone of sildenafil
in the PDE5A1 structure [29]. However, the nitrophenyl group
and the naphthyridine ring of NVP share the interaction with
the conserved phenylalanine residue, resulting in a tilt to each
ring plane. In addition, NVP forms van der Waals interactions
with Tyr159, Met273, Asn321, Ile336, Phe340, Met357 and Ser368 in
PDE4D. All of these residues are identical across the four PDE4
subfamilies.
Subtle, but significant, differences at the active sites of PDE4
subfamilies
In spite of such overall similarity, structural superposition shows
subtle, but significant, differences at the active sites of the PDE4
subfamilies. Among the PDE4 subfamilies, PDE4B and PDE4D
are most comparable. Thus almost all the residues of PDE4B
and PDE4D that are involved in inhibitor binding have the
same conformation with small positional differences. Met451 of
PDE4B, which connects with helices H14 and H15, is a clear
exception, as it exhibits significant conformational changes from
Met357 of PDE4D (Figure 4c). Since this methionine residue has
c© The Authors Journal compilation c© 2007 Biochemical Society
Crystal structures of PDE4 subfamilies 197
Figure 2 Ribbon diagrams of PDE4 subfamily members 4A, 4B, 4C and 4D
The broken lines in PDE4C represent the disordered residues 333–345 of the H-loop and 465–490 of the M-loop. C-term, C-terminus; N-term, N-terminus.
relatively larger B-factors (47.7, 60.6 and 43.8 compared with
37.4, 42.9 and 26.3 Å2 of overall averages in PDE4A, PDE4B
and PDE4D respectively), its position is more flexible. Although
the conformational changes of the methionine residue would
be expected to have an impact on the inhibitor binding, there
may be other unidentified elements that compromise this effect.
Thus these comparative studies imply that the catalytic domains
of PDE4B and PDE4D are likely to have similar affinities for
competitive inhibitors.
The structural superposition of PDE4A on PDE4D shows more
divergence than PDE4B, as indicated by average displacement of
0.34 Å for Cα of 15 active-site residues of PDE4A and PDE4D
compared with 0.24 Å for those of PDE4B and PDE4D. In
addition, Ala363–Ser368 of PDE4D show an average positional shift
of 1.1 Å for the Cα atoms of their equivalents in PDE4A, which is
about twice the overall average between the structures of PDE4A
and PDE4D. Since these residues are next to the invariant Gln369
that is critical for binding of inhibitors and substrates, such a
positional shift would be expected to affect the binding affinity of
inhibitors.
The positional difference between residues of PDE4C and
PDE4D are more obvious. This is shown in Figure 4(D)
and also by the average displacement of 0.49 Å for the Cα
atoms of 12 active site residues between PDE4C and PDE4D.
In addition, the conformation of the side chain of Phe340
of PDE4D swings to a different direction from that observed
in PDE4C. Furthermore, the majority of the residues in the
H- and M-loops, which are important for inhibitor binding, are
disordered in PDE4C. Although the structure PDE4C in complex
with NVP is not available, we believe that the conformation of the
unliganded PDE4C simulates that in the complex state because
the conformations of the unliganded PDE4B and PDE4D are very
similar to the NVP- and other inhibitor-bound states, as shown
by the structure superposition. Therefore these observations
imply that the catalytic site of PDE4C is unique among PDE4
subfamilies, but those of the PDE4B and PDE4D can be
categorized together. In short, the structural studies suggest that
it may be relatively easier to develop PDE4C-selective inhibitors,
but more difficult to obtain inhibitors with PDE4B and PDE4D
selectivity.
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Figure 3 Conformation of NVP
(A) Electron density map for inhibitor NVP. The F o−F c map was calculated from the PDE4A10 structure with omission of NVP and contoured at 2σ . (B) The PDE4B2B map was contoured at 2σ .
(C) The PDE4D2 map was contoured at 2.5σ . (D) Superposition of NVPs from PDE4A (cyan), PDE4B (green) and PDE4D (gold). (E) A 90◦ view of the NVP superposition from (D).
DISCUSSION
Implications of the subfamily selectivity of PDE4 inhibitors
Although poor subfamily-selectivity of PDE4 inhibitors is thought
to be one possible cause of their side effects, only a few subtype-
selective PDE4 inhibitors that exhibit a limited degree of selectiv-
ity for PDE4D have been reported [22,27,28]. The structures of the
PDE4 subfamilies in complex with NVP provide an explanation
to why it is so difficult to develop PDE4 subfamily-selective
inhibitors. First, residues that are involved in direct interaction
with NVP or located at the second shell of the active site are
identical in all the PDE4 subfamilies. This suggests a similar
energy for inhibitor binding. Secondly, structural superposition
reveals that the active site has a similar conformation and pocket
size in all of the four PDE4 subfamilies. Thirdly, the deeply
buried pocket available for inhibitor binding within the active
site implies that the pocket itself dominates subfamily selectivity.
These observations imply severe limitations for development of
active-site-directed PDE4 subfamily inhibitors.
On the other hand, our comparative structural studies identify,
for the first time, subtle, but significant, differences in the active
site of the PDE4 subfamilies. Indeed, PDE4A shows the
significant displacement of the N-terminal residues (Ala575–Ser580)
of the invariant glutamine residue (Gln581) that is critical for
binding of both substrates and inhibitors, and several of the
active-site residues of PDE4C are disordered. These structural
differences potentially provide a new basis for the design of novel
classes of PDE4 subfamily-selective inhibitors.
We also note that other factors in full-length PDE4 isoforms
may impinge on the function and structure of the catalytic unit
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Figure 4 Binding of NVP to the PDE4 subfamilies
(A) The interaction of NVP (golden bonds) with the PDE4D2 residues (green bonds). Broken lines represent the hydrogen bonds or metal co-ordination. (B) Superposition of PDE4A10–NVP (blue
and orange bonds) on PDE4D2–NVP (green bonds). Residue numbers, such as M357/569, are those of PDE4D2/PDE4A10 respectively. Ser368 of PDE4D2 shows a significant shift from Ser580 of
PDE4A10. (C) Superposition of PDE4B2B–NVP (blue and orange) on PDE4D2–NVP (green). (D) Superposition of PDE4C2 (blue) on PDE4D2–NVP (green and orange). Residues Met479, Ser490
and Gln491 of PDE4C2 are disordered and are not shown. Significant conformational changes are visible between PDE4C and PDE4D. For example, the side-chain Phe340 of PDE4D2 has a different
orientation from Phe462 of PDE4C2.
and may also be usefully exploited in developing other classes of
PDE4-selective inhibitors. Thus the UCR1 and UCR2 domains,
which are located immediately N-terminal to the catalytic unit,
act to direct the functional changes in PDE4 catalytic activity,
presumably due to altered conformation of the PDE4 catalytic
domain upon phosphorylation by PKA [41], ERK (extracellular-
signal-regulated kinase) [42] and a kinase downstream of PI3K
(phosphoinositide 3-kinase) [43]. Indeed, PKA phosphorylation
of PDE4D3, which is mediated via UCR1, has been shown to
lead to alterations in sensitivity to inhibition of rolipram [38,41].
In addition, the binding of XAP2 (X-associated protein 2)/AIP
(aryl hydrocarbon receptor-interacting protein) to PDE4A5 has
been shown to regulate the catalytic activity of this isoform
[37]. Other proteins such as ERK2 [42], β-arrestin [44] and
AKAP18 (A-kinase-anchoring protein 18) [45] also bind to
the PDE4 catalytic unit and may effect subtle conformational
changes. These proteins may interact directly with the surface
residues of the pocket, such as Ser226 of the H-loop and
Arg342 of the M-loop in PDE4D, thus affecting the inhibitor
selectivity.
The present study provides the first structural insights into
the catalytic domains of PDE4A and PDE4C coupled with the
first structural evaluation of PDE4 catalytic units in complex
with a subfamily-selective inhibitor. These structures may lead
to the development of strategies that might be adopted to design
subfamily-selective inhibitors. The structural information of the
c© The Authors Journal compilation c© 2007 Biochemical Society
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present study also indicates the likelihood of changes occurring
in the conformation of the active site through protein–protein
interactions and through the action of the UCR1 and UCR2
modules.
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34 Brünger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve,
R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S. et al. (1998) Crystallography
and NMR system: a new software suite for macromolecular structure determination.
Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905–921
35 Wang, H., Liu, Y., Chen, Y., Robinson, H. and Ke, H. (2005) Multiple elements jointly
determine inhibitor selectivity of cyclic nucleotide phosphodiesterases 4 and 7.
J. Biol. Chem. 280, 30949–30955
36 Wang, H., Liu, Y., Hou, J., Zheng, M., Robinson, H. and Ke, H. (2007) Structural insight
into substrate specificity of phospodiesterase 10. Proc. Natl. Acad. Sci. U.S.A. 104,
5782–5787
37 Bolger, G. B., Peden, A. H., Steele, M. R., MacKenzie, C., McEwan, D. G., Wallace, D. A.,
Huston, E., Baillie, G. S. and Houslay, M. D. (2003) Attenuation of the activity of the
cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.
J. Biol. Chem. 278, 33351–33363
38 Alvarez, R., Sette, C., Yang, D., Eglen, R. M., Wilhelm, R., Shelton, E. R. and Conti, M.
(1995) Activation and selective inhibition of a cyclic AMP-specific phosphodiesterase,
PDE-4D3. Mol. Pharmacol. 48, 616–622
39 Xu, R. X., Hassell, A. M., Vanderwall, D., Lambert, M. H., Holmes, W. D., Luther, M. A.,
Rocque, W. J., Milburn, M. V., Zhao, Y., Ke, H. and Nolte, R. T. (2000) Atomic structure of
PDE4: insight into phosphodiesterase mechanism and specificity. Science 288,
1822–1825
40 Houslay, M. D. and Adams, D. R. (2003) PDE4 cAMP phosphodiesterases: modular
enzymes that orchestrate signalling cross-talk, desensitisation and compartmentalization.
Biochem. J. 370, 1–18
41 Hoffmann, R., Wilkinson, I. R., McCallum, J. F., Engels, P. and Houslay, M. D. (1998)
Cyclic AMP specific phosphodiesterase HSPDE4D3 mutants which mimic activation and
changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser54:
generation of a molecular model. Biochem. J. 333, 139–149
c© The Authors Journal compilation c© 2007 Biochemical Society
Crystal structures of PDE4 subfamilies 201
42 Hoffmann, R., Baillie, G. S., MacKenzie, S. J., Yarwood, S. J. and Houslay,
M. D. (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific
phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. EMBO J. 18,
893–903
43 Hill, E. V., Sheppard, C. L., Cheung, Y. F., Gall, I., Krause, E. and Houslay, M. D. (2006)
Oxidative stress employs phosphatidyl inositol 3-kinase and ERK signalling pathways to
activate cAMP phosphodiesterase-4D3 (PDE4D3) through multi-site phosphorylation at
Ser239 and Ser579. Cell. Signalling 18, 2056–2069
44 Perry, S. J., Baillie, G. S., Kohout, T. A., McPhee, I., Magiera, M. M., Ang, K. L., Miller,
W. E., McLean, A. J., Conti, M., Houslay, M. D. and Lefkowitz, R. J. (2002) Targeting of
cyclicAMPdegradationtoβ2-adrenergicreceptorsbyβ-arrestins. Science 298, 834–836
45 Stefan, E., Wiesner, B., Baillie, G. S., Mollajew, R., Henn, V., Lorenz, D., Furkert, J.,
Santamaria, K., Nedvetsky, P., Hundsrucker, C. et al. (2007) Compartmentalization of
cAMP-dependent signaling by phosphodiesterase-4D is involved in the regulation
of vasopressin-mediated water reabsorption in renal principal cells. J. Am. Soc. Nephrol.
18, 199–212
Received 20 July 2007/17 August 2007; accepted 30 August 2007
Published as BJ Immediate Publication 30 August 2007, doi:10.1042/BJ20070970
c© The Authors Journal compilation c© 2007 Biochemical Society
